People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Pharmaceuticals, Biotechnology, Retailing, Healthtech, Other Technology, Software / Tech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Orexigen Therapeutics, Inc. | — | Pharmaceuticals | Series D+ | $274.6M | $1.8B | 2016 |
| Evofem Biosciences, Inc. | — | Biotechnology | Series B | $133.6M | $4.3M | 2017 |
| MRMMK Hold Co. | — | Retailing | Series C | $62.4M | $363.2M | 2015 |
| Bainbridge Health, Inc. | — | Healthtech | Seed | $9.3M | $10.9M | 2022 |
| Profectus Biosciences, Inc | — | Biotechnology | Series A | $7.3M | $10.8M | 2009 |
| ASPi Solutions, Inc. | — | Other Technology | Seed | $5.8M | $9.0M | 2022 |
| Fusion Recruiting Labs, Inc. | — | Software / Tech | Seed | $2.0M | $68.1M | 2019 |
Thomas Lynch at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Thomas Lynch on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Murphy | 1 | 21 |
| Louis C. Bock | 1 | 7 |
| Brian H. Dovey | 1 | 7 |
| Mike Murphy | 1 | 7 |
| Donald Caldwell | 1 | 6 |
| Kim Kamdar | 1 | 6 |
| Sean O'Neill | 1 | 5 |
| William Hall | 1 | 5 |
| Lota S Zoth | 1 | 4 |
| Robert Lynch | 1 | 3 |
| Shahram Hejazi | 1 | 3 |
| Thomas F. Darden II | 1 | 3 |
| Jenny Yip | 1 | 3 |
| Stewart Greenebaum | 1 | 2 |
| Joseph Hagan | 1 | 2 |
| Patrick J. Mahaffy | 1 | 2 |
| Preston Klassen | 1 | 2 |
| Brian Adamsky | 1 | 2 |
| William A Haseltine | 1 | 2 |
| Frederick C. Tecce | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.